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. INTRODUCTION
Herbal remedies are widely used in the modern world as people believe that "herbal" means naturally "safe". Parallel to this increasing interest, companies produce huge amounts of dietary supplements with low quality raw materials and sometimes what's claimed on the label is lacked inside. Besides dietary supplements, traditional herbal medicinal products are regulated same way as the conventional medicines. Registration of herbal and conventional medicines requires application dossiers known as common technical document (CTD). The CTD consists of five modules and the third one contains all the required quality information and data about the product [1] . Module 3.2.S.4 has all the information for the active ingredient and 3.2.P.3.3 section of CTD describes the production steps of the product. 3.2.P.5.2 states the applied analytical procedures for drug products meanwhile 3.2.P.5.3 section covers all the analytical method validation data whether the product is herbal or conventional [2] . These registration requirements guarantees that the traditional herbal medicinal products are being manufactured with highest quality plant extracts and controlled in every steps of production.
Chasteberry tree or chaste tree (Vitex agnus-castus L.) -a member of Verbenaceae family-is a small shrub native to European, Mediterranean, and Central Asian countries. It has been long used traditionally for its medicinal properties indicated to female reproduction conditions like premenstrual problems and hyperprolactinemia [3, 6] . Dry extract of Vitex agnus-castus L. fruits also has a well-established use described in European Union herbal monograph with a daily dose of 20 mg for female adults [7] . Derived information about marketed products containing Vitex agnus-castus L. in European Union signifies that most of the active ingredients are usually dry extracts with a posology of 4 to 20 mg per day indicated to irregular menstruation, premenstrual syndrome and mastodynia. Also tinctures, liquid extracts and powdered herbal substances are being used for the same purposes with different posologies [8] .
In European Pharmacopoeia (EP), agnus-castus fruit dry extract is standardised to a methoxylated flavonol called casticin -also known as vitexicarpin-not less than 0.1% in the extract [9] . Casticin was also reported for its anti-inflammatory, anti-malarial, anti-oxidant and anti-cancer activities [10] [11] [12] [13] . There are several registered traditional herbal medicinal products in European Union containing agnus-castus fruit extract. In this study we developed a stable solid oral formulation and validated the assay method to evaluate the stability of products to comply CTD requirements.
RESULTS AND DISCUSSION

Optimization of HPLC methods to quantify casticin in herbal extracts and tablets
Various C18 columns were used to achieve the best separation and peak shapes to quantify casticin content of agnus-castus fruit extracts and herbal tablets. The column and mobile phase used in EP method [9] for determining casticin content of agnus-castus dry extract gives a resolution of 1.5 between penduletin and casticin so a different column was selected to achieve a better resolution. Method parameters were given in Table 1 . 
Method validation
Method validation was performed according to International conference on harmonization (ICH) Q2(R1) Validation of analytical procedures: text and methodology guidelines [14] .
Product and placebo
The products are manufactured according to the formulation given in Table 2 . Placebo used in specificity study was formulated the same way except extract itself. For accuracy studies 80% and 120% extract containing formulations were also prepared with 16 mg extract with 64 mg lactose and 24 mg extract with 56 mg lactose respectively. 
Specificity
Specificity is the ability to assess the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components. To assess the specificity with casticin; methanol as solvent, mobile phase, placebo, agnus-castus fruit dry extract reference substance (HRS) and the product itself were injected to the system according to the method described in material methods section. Table 3 shows the results of specificity test and chromatogram of the product could be seen in Figure  1 . 
Chromatogram of tablets containing agnus-castus extract.
System repeatability, system suitability, range and linearity
To achieve system repeatability, system suitability and linearity; 50%, 80%, 100%, 120%and 150% concentration of agnus-castus fruit dry extract HRS was prepared according to the method described in material and methods section. 100% concentration solution was injected six times and the others were injected three times to achieve linearity, system repeatability and system suitability. Table 4 illustrate the results for casticin peak areas while Figure 2 demonstrates the calibration curve for linearity test. Acceptance for the range test were based on the following; range of the method should be linear, accurate, and repeatable between the 80% and the 120% of the solution and the results compiles with the criteria.
Accuracy
The accuracy of method was determined by means of recovery data. For this purpose formulations which contain 16, 20 and 24 mg extract were used to achieve 80%, 100% and 120% of the real concentrations respectively. Three sets of samples were analysed for each concentration and each sample tested for twice. The amount of agnus-castus extracts in the products were calculated according to the formula given below and Table 5 demonstrates the accuracy studies.
In the formula; A1: area of casticin in product, A2: area of casticin in HRS, m1: HRS in reference solution in miligrams, p1: Casticin percentage in HRS, p2: Casticin percentage in raw material (Casticin content should be quantified in raw material before use).
Agnus-castus extract in tablets (mg)= A1 x m1 x p1 A2 x 5 x p2 (Eq. 1) Table 4 . System repeatability, system suitability, range and linearity data. The calculated RSD% was ≤ 2.0 for system repeatability and the system suitability tests complies with the criteria.
Concentration
Casticin Peak Area Calibration curve for casticin plotted between the correlation of extract concentration (mg) and HPLC peak area.
Precision
The precision of an analytical procedure is the degree of agreement among individual test results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision of the method assessed in terms of repeatability, intermediate precision and reproducibility. Reproducibility refers to the use of the analytical procedure in different laboratories, as in a collaborative study. Intermediate precision (also known as ruggedness) expresses within-laboratory variation, as on different days, or with different analysts or equipment within the same laboratory. Repeatability refers to the use of the analytical procedure within a laboratory over a short period of time using the same analyst with the same equipment. Table 6 shows intermediate precision and repeatability data while Table 7 demonstrates the reproducibility of the method. 
Solution stability
Test solutions used in accuracy tests were kept in 4 °C and 25 °C in the dark for 48 hours and analysed again to achieve solution stability. Solution remained stable in the solution as seen in Table 9 . Table 9 . The results of solution stability data. Area  706102  707185  707456  707625  707248  707247  707376  706982  707325  707806  707882  707452  706668  706924  707016  707775 707123 707043
Fresh Solution Casticin Peak Area 48 hours in 4 °C Casticin Peak Area 48 hours in 25 °C Casticin Peak
Formulation stability
Accelerated and long term stability tests were carried out to confirm the stability of the herbal product in primary packaging material according to ICH Q1A(R2); Stability testing of new drug substances and products guidelines [16] . Accelerated stability conditions were as follows; 40 ± 2°C, 75% ± 5% R.H meanwhile long term stability conditions were 25 ± 2°C, 60% ± 5% R.H. Table 10 shows the accelerated stability test results. Long term stability control test periods were 1, 3, 6, 9, 12, 18, 24th months and the results were in the limits. 
Physical properties
Disintegration tests of tablets were performed with a PTZ-S single basket tablet disintegrator (Pharma Test Apparatebau AG/Germany). All the tablets were disintegrated less than 20 minutes (17.8 min. average). As an in-process control parameter, friability test of tablets before coating were performed with PTF 100 single drum friability test instrument (Pharma Test Apparatebau AG/Germany) and not more than 0.6% of tablet weight was lost. A dissolution test was not reported in this study because disintegration is shown to be more discriminating than dissolution as stated by European Medicine Agency [17] .
CONCLUSION
Researches show that products containing Vitex agnus-castus L. fruit extract are as effective as the prescription drugs. However there are only a few registered herbal medicinal products on the market and the quality of dietary supplements are questionable. The following study demonstrates a stable oral formulation and a fully validated analytical method to comply the related parts of CTD and could be used while registering agnus-castus as traditional herbal medicinal product.
MATERIALS AND METHODS
Methanol and orthophosphoric acid were purchased from Merck (Darmstadt, Germany). Reference substances of agnus-castus fruit dry extract HRS was purchased from EDQM (Strasburg, France). EP grade agnus-castus fruit dry extract with a casticin content of 0.45% by weight was purchased from Naturex (Avignon, France). Naturex extract was quantified with EDQM reference substances before using as raw material to produce the dosage forms. The methods were developed and validated using a Shimadzu UFLC Prominence (Kyoto, Japan) system coupled with a PDA detector. Column was purchased from GLSciences (Japan). Analytical method parameters are listed in Table 1 . Hitachi Aquacounter AQV 300 (Tokyo, Japan) was used to quantify water amount in the formulations. Lactopress anhydrous fine powder with a d90 value of 70 micron and Pharmacel 101 with a d90 value of 120 micron were purchased from DFE Pharma (Goch, Germany). Opadry 200 was purchased from local distributor of Colorcon (Harleysville, PA, USA). Magnesium stearate (Ligamed MF-2-V, Peter Greven, Bad Muenstereifel, Germany) and colloidal silica (HDK N20, Wacker Chemie AG, München, Germany) were pharmaceutical grade and purchased from the related brands.
Formulating and producing the dosage forms
Agnus-castus dry extract and the rest of excipients were mixed in a cubic mixer for 30 minutes according to the unit formula given in Table 2 . After mixing the ingredients, the tablets were pressed with a Karnavati Mini Press I (Gujarat, India) small-scale compression machine. Placebo was prepared same way without the extract itself. 80% and 120% extract containing formulations were prepared with 16 mg extract-64 mg lactose and 24 mg extract-56 mg lactose respectively for accuracy studies in method validation. Prism LABOcoata-12 (Gujarat, India) tablet coating machine was used for film coating with 3% solution of Opadry 200. Finally 30 tablets were packaged with PVC-aluminium blisters.
Assay method
To prepare reference solution; 100 mg Agnus-castus fruit dry extract HRS was introduced into a 50 mL volumetric flask. Flask was filled with 40 mL of methanol and sonicated for 15 minutes. After cooling to the room temperature filled up to the volume with methanol, filtered through a 50 µm PTFE membrane filter into an analytical vial and 20 µL of the solution was subjected to injection.
Sample solution was prepared same way except five pounded tablets were introduced to the volumetric flask. To achieve the system suitability, resolution between penduletin and casticin should be ≥2 and RSD% of casticin peak areas should be ≤2 for two sequential reference solution injection. The amount of agnus-castus extract in dosage forms could be calculated with the formula given in 2.2.4 Accuracy section.
Stability studies
Accelerated and long term stability tests for products in primary packaging material were performed in a Binder KBF 115 (Tuttlingen, Germany) stability chamber. The conditions and sampling periods were described in 2.3 Formulation Stability section.
